Jane Street Group LLC Sells 89,680 Shares of AlloVir, Inc. (NASDAQ:ALVR)

Jane Street Group LLC lessened its holdings in AlloVir, Inc. (NASDAQ:ALVR) by 51.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 83,351 shares of the company’s stock after selling 89,680 shares during the period. Jane Street Group LLC owned about 0.07% of AlloVir worth $67,000 at the end of the most recent reporting period.

Separately, Point72 Asia Singapore Pte. Ltd. bought a new position in AlloVir in the 2nd quarter worth $55,000. Institutional investors own 66.05% of the company’s stock.

AlloVir Stock Performance

NASDAQ:ALVR opened at $0.38 on Thursday. The stock has a 50-day simple moving average of $0.52 and a two-hundred day simple moving average of $0.69. The firm has a market capitalization of $44.04 million, a PE ratio of -0.43 and a beta of 0.65. AlloVir, Inc. has a 52-week low of $0.38 and a 52-week high of $1.05.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.